J Drugs Dermatol. 2022 Aug 1;21(8):914-916. doi: 10.36849/JDD.6828.
The aim of this retrospective study of patients affected by plaque psoriasis who underwent tildrakizumab therapy was to describe and compare the response of the nail psoriasis and the plaque psoriasis elsewhere in the body. Eight patients treated with tildrakizumab, 4 males and 4 females with a mean age of 61 years affected by psoriasis (mean baseline-PASI:13) with nail involvement (mean baseline mNAPSI: 51.9), were followed for at least 20 weeks. At week 4, the mean PASI was 6.6 (49% improvement), and the mean mNAPSI was 30.8 (40.6% improvement). At week 20, the mean PASI was 2.1 (84% improvement), and the mean mNAPSI was 5.1 (90% improvement). The fast improvement of the nail psoriasis in the 8 patients was unexpected, considering the fact that Tildrakizumab is a molecule that in RCTs (reSURFACE-1 and 2) studies has proved to be efficacious against plaque psoriasis but not strikingly fast, requiring at least 20 weeks to achieve the best PASI-improvements in most patients. Evidence regarding nail improvement during tildrakizumab are scarce. Studies including a higher number of patients are required in order to confirm our observation of the fast improvement of nail psoriasis during Tildrakizumab. J Drugs Dermatol. 2022;21(8):914-916. doi:10.36849/JDD.6828.
本回顾性研究旨在描述和比较接受替度鲁单抗治疗的斑块型银屑病患者的指甲银屑病和身体其他部位斑块型银屑病的反应。8 名接受替度鲁单抗治疗的男性和女性患者，平均年龄 61 岁，患有银屑病（平均基线 PASI：13）并伴有指甲受累（平均基线 mNAPSI：51.9），至少随访 20 周。第 4 周时，平均 PASI 为 6.6（改善 49%），平均 mNAPSI 为 30.8（改善 40.6%）。第 20 周时，平均 PASI 为 2.1（改善 84%），平均 mNAPSI 为 5.1（改善 90%）。考虑到替度鲁单抗是一种在 RCT（reSURFACE-1 和 2）研究中已被证明对斑块型银屑病有效的分子，但起效并不明显，大多数患者至少需要 20 周才能达到最佳 PASI 改善，因此这 8 名患者的指甲银屑病快速改善是出乎意料的。关于替度鲁单抗治疗期间指甲改善的证据很少。需要纳入更多患者的研究来证实我们观察到的替度鲁单抗治疗期间指甲银屑病快速改善的结果。J 皮肤病药物学杂志。2022;21(8):914-916. doi:10.36849/JDD.6828.
